Agios to Webcast Conference Call of First Quarter 2023 Financial Results on May 4, 2023
Agios Pharmaceuticals (Nasdaq: AGIO) will host a conference call and live webcast on May 4, 2023, at 8:00 a.m. ET to discuss its first quarter 2023 financial results and other business highlights. The event will be accessible via the company's website, with an archived replay available shortly after the event.
The company is recognized for its pioneering work in cellular metabolism and markets the first disease-modifying therapy for patients with PK deficiency. Agios is actively advancing a clinical pipeline focused on various rare diseases and has a potential therapeutic candidate in preclinical development for phenylketonuria.
- Hosting a conference call to discuss Q1 2023 financial results, indicating transparency and engagement with investors.
- Advancing a robust clinical pipeline with programs targeting rare diseases, which could lead to potential revenue growth.
- None.
CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 4, 2023, at 8:00 a.m. ET to report its first quarter 2023 financial results and other business highlights.
A live webcast can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.agios.com. The webcast will be archived and made available for replay on the company’s website beginning approximately two hours after the event.
About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has a PAH stabilizer in preclinical development as a potential treatment for phenylketonuria (PKU) and deep scientific expertise in classical hematology. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor Contact
Cecilia Jones, Chief Financial Officer
Agios Pharmaceuticals
IR@agios.com
Media Contact
Dan Budwick
1AB Media
dan@1abmedia.com
FAQ
What date will Agios report its Q1 2023 financial results?
How can I access the Agios conference call?
What is the focus of Agios Pharmaceuticals?
